MedTrace Logo

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

NCT01251588 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee.

Conditions

  • Articular Cartilage Defects

Interventions

BIOLOGICAL

autologous cultured chondrocytes on porcine collagen membrane

Implantation received in the previous MACI00206 study

PROCEDURE

Microfracture

Arthroscopic Microfracture treatment received in the previous MACI00206 study

Sponsors & Collaborators

  • Vericel Corporation

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Czechia
  • France
  • Netherlands
  • Norway
  • Poland
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251588 on ClinicalTrials.gov